Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar i disorder: A 26-week, open-label, continuation study

Journal of Child and Adolescent Psychopharmacology

Volumn 23, Issue 7, 2013, Pages 490-501

  Findling, Robert L ^a   Pathak, Sanjeev ^b   Earley, Willie R ^c   Liu, Sherry ^b   Delbello, Melissa ^d  

^a JOHNS HOPKINS CHILDREN S CENTER   (United States)

^b ASTRAZENECA   (United Kingdom)

^c FOREST RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IBUPROFEN; LORAZEPAM; METHYLPHENIDATE; MOOD STABILIZER; PARACETAMOL; PLACEBO; PSYCHOSTIMULANT AGENT; QUETIAPINE; TRIACYLGLYCEROL;

ADOLESCENT; AGITATION; ANXIETY; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV; EVENING DOSAGE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; FEVER; GROWTH, DEVELOPMENT AND AGING; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; IRRITABILITY; JUVENILE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NOSE OBSTRUCTION; OPEN STUDY; OUTCOME ASSESSMENT; SCHIZOPHRENIA; SCHOOL CHILD; SEDATION; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TRIACYLGLYCEROL BLOOD LEVEL; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; VOMITING; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHILD; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; SCHIZOPHRENIA;

EID: 84884507369     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2012.0092     Document Type: Article

References (61)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000.
2. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676, 1989.
3. Berk M, Hallam K, Malhi GS, Henry L, Hasty M, Macneil C, Yucel M, Pantelis C, Murphy B, Vieta E, Dodd S, McGorry PD: Evidence and implications for early intervention in bipolar disorder. J Ment Health 19:113-126, 2010.
4. Birmaher B, Axelson D, Strober M, Gill MK, Valeri S, Chiappetta L, Ryan N, Leonard H, Hunt J, Iyengar S, Keller M: Clinical course of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry 63:175-183, 2006.
5. Brannan AM, Heflinger CA, Bickman L: The caregiver strain questionnaire: Measuring the impact on the family of living with a child with serious emotional disturbance. J Emot Behav Disord 5:212-222, 1997.
6. Centers for Disease Control and Prevention: Growth charts, 2000. Available at http://www.cdc.gov/growthcharts/Accessed February 5, 2013.
7. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use on children and adolescents. JAMA 302:1765-1773, 2009.
8. DelBello MP, Adler CM, Whitsel RM, Stanford KE, Strakowski SM: A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J Clin Psychiatry 68:789-795, 2007.
9. DelBello MP, Chang K, Welge JA, Adler CM, Rana M, Howe M, Bryan H, Vogel D, Sampang S, Delgado SV, Sorter M, Strakowski SM: A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 11:483-493, 2009.
10. DelBello MP, Kowatch RA: Pharmacological interventions for bipolar youth: Developmental considerations. Dev Psychopathol 18:1231-1246, 2006.
11. Findling R, McKenna K, Earley W, Stankowski J, Pathak S: Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 22:327-342, 2012.
12. Findling RA, Johnson JL, McClellan J, Frazier JA, Vitiello B, Hamer RM, Lieberman JA, Ritz L, McNamara NK, Lingler J, Hlastala S, Pierson L, Puglia M, Maloney AE, Kaufman EM, Noyes N, Sikich L: Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 49:583-594, 2010.
13. Findling RL: Diagnosis and treatment of bipolar disorder in young patients. J Clin Psychiatry 70:e45, 2009.
14. Findling RL, Nyilas M, Forbes RA, McQuade RD, Jin N, Iwamoto T, Ivanova S, Carson WH, Chang K: Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: A randomized, double-blind, placebo-controlled study. J Clin Psychiatry 70:1441-1451, 2009.
15. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH: A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165:1432-1441, 2008.
16. Fleischhaker C, Schulz E, Tepper K, Martin M, Hennighausen K, Remschmidt H: Long-term course of adolescent schizophrenia. Schizophr Bull 31:769-780, 2005.
17. Fraguas D, Correll CU, Merchan-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, Arango C: Efficacy and safety of secondgeneration antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 21:621-645, 2010.
18. Geller B, Tillman R, Bolhofner K, Zimerman B, Strauss NA, Kaufmann P: Controlled, blindly rated, direct-interview family study of a prepubertal and early-adolescent bipolar I disorder phenotype: Morbid risk, age at onset, and comorbidity. Arch Gen Psychiatry 63:1130-1138, 2006.
19. Goldstein TR, Birmaher B, Axelson D, Ryan ND, Strober MA, Gill MK, Valeri S, Chiappetta L, Leonard H, Hunt J, Bridge JA, Brent DA, Keller M: History of suicide attempts in pediatric bipolar disorder: Factors associated with increased risk. Bipolar Disord 7:525-535, 2005.
20. Gould MS, Greenberg T, Velting DM, Shaffer D: Youth suicide risk and preventive 23 interventions: A review of the past 10 years. J Am Acad Child Adolesc Psychiatry 42:386-405, 2003.
21. Guy W: Abnormal Involuntary Movement Scale. In: ECDEU Assessment Manual for Psychopharmacology, revised ed. Rockville, MD: U.S. Department of Health, Education, and Welfare, 1976, pp. 534-537
22. Guy W, Bonato RR: CGI clinical global impression. In: Manual for the ECDEU Assessment Battery. Revised 2nd ed. Chevy Chase, MD: U.S. Department of Health, Education and Welfare, 1970, pp. 12-1-12-6
23. Haas M, DelBello MP, Pandina G, Kushner S, Van Hove I, Augustyns I, Quiroz J, Kusumakar V: Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: A randomized, double-blind, placebo-controlled study. Bipolar Disord 11:687-700, 2009a.
24. Haas M, Unis AS, Aementeros J, Copenhaver MD, Quiroz JA, Kushner SF: A 6-week, randomized, double-blind, placebocontrolled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 19:611-621, 2009b.
25. Jensen JB, Kumra S, Leitten W, Oberstar J, Anjum A, White T, Wozniak J, Lee SS, Schulz SC: A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders. J Child Adolesc Psychopharmacol 18:317-326, 2008.
26. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS). Schizophr Bull 13:261-276, 1987.
27. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K SADSPL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988, 1997.
28. Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Tohen M: Olanzapine versus placebo in adolescents with schizophrenia: A 6-week, randomized, double-blind, placebocontrolled trial. J Am Acad Child Adolesc Psychiatry 48:60-70, 2009.
29. Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, De Thomas C, Kafantaris V, Correll CU, Kane JM: Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: A 12-week randomized and double-blind comparison. Biol Psychiatry 63:524-529, 2008.
30. Lay B, Blanz B, Hartmann M, Schmidt M: The psychosocial outcome of adolescent schizophrenia: A 12-year follow-up. Schizophr Bull 26:801-816, 2000.
31. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM: The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord 31:281-294, 1994.
32. Loranger AW: Sex difference in age of onset of schizophrenia. Arch Gen Psychiatry 41:157-161, 1984.
33. Maayan L, Correll CU: Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 21:517-535, 2011.
34. Mattai AK, Hill JL, Lenroot RK: Treatment of early onset schizophrenia. Curr Opin Psychiatry 23:304-310, 2010.
35. McConville BJ, Arvanitis LA, Thyrun PT, Yeh C, Wilkinson LA, Chaney RO, Foster KD, Sorter MT, Friedman LM, Brown KL, Heubi JE: Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 61:252-260, 2000.
36. McIntyre RS, Jerrell JM: Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med 162:929-935, 2008.
37. Moreno C, Merchan-Naranjo J, Alvarez M, Baeza I, Alda JA, Mart?́nez-Cantarero C, Parellada M, Sánchez B, de la Serna E, Giráldez M, Arango C: Metabolic effects of second-generation antipsychotics in bipolar youth: Comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord 12:172-184, 2010.
38. Morris NM, Udry JR: Validation of a self-administered instrument to assess stage of adolescent development. J Youth Adolesc 9:271-280, 1980.
39. Pathak S, Findling RL, Earley W, Acevedo LD, Stankowski J, Del-Bello MP: Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: A 3-week, double-blind, placebo-controlled trial. J Clin Psychiatry 74:e100-e109, 2013.
40. Pavuluri MN, Henry DB, Findling RL, Parnes S, Carbray JA, Mohammed T, Janicak PG, Sweeney JA: Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar Disord 12:593-605, 2010.
41. Perlis RH, Miyahara S, Marangell LB, Wisniewski SR, Ostacher M, DelBello MP, Bowden CL, Sachs GS, Nierenberg AA, STEP-BD Investigators: Long-term implications of early onset in bipolar disorder: Data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 55:875-881, 2004.
42. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ: The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168:1266-1277, 2011.
43. Posner K, Oquendo MA, Gould M, Stanley B, Davies M: Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 164:1035-1043, 2007.
44. Post RM, Leverich GS, Xing G, Weiss RB. Developmental vulnerabilities to the onset and course of bipolar disorder. Dev Psychopathol 13:581-598, 2001.
45. Post RM, Weiss RB, Leverich GS, George MS, Frye M, Ketter TA: Developmental psychobiology of cyclic affective illness: Implications for early therapeutic intervention. Dev Psychopathol 8:273-305, 1996.
46. Reichert A, Kreiker S, Mehler-Wex C, Warnke A: The psychopathological and psychosocial outcome of early-onset schizophrenia: Preliminary data of a 13-year follow-up. Child Adolesc Psychiatry Ment Health 2:6, 2008.
47. Schimmelmann BG, Mehler-Wex C, Lambert M, Schulze-zur-Wiesch C, Koch E, Flechtner HH, Gierow B, Maier J, Meyer E, Schulte-Markwort M: A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders. J Child Adolesc Psychopharmcol 17:768-778, 2007.
48. Seroquel-(quetiapine fumarate) prescribing Information, 2012. Available at http://www1.astrazeneca-us.com/pi/Seroquel.pdf Accessed February 5, 2013.
49. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S: A children's global assessment scale (CGAS). Arch Gen Psychiatry 40:1228-1231, 1983.
50. Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R, Pupo-Guillen M: A study of quetiapine: Efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 11:415-424, 2001.
51. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA: Double-blind comparison of first-and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165:1420-1431, 2008.
52. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212 Suppl 44:11-19, 1970.
53. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W: Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): The CGI-BP. Psychiatr Res 73:159-171, 1997.
54. Strober M, Schmidt-Lackner S, Freeman R, Bower S, Lampert C, DeAntonio M: Recovery and relapse in adolescents with bipolar affective illness: A five-year naturalistic, prospective followup. J Am Acad Child Adolesc Psychiatry 34:724-731, 1995.
55. Tanner JM: Growth at Adolescence. Oxford: Blackwell Scientific Publications, 1962.
56. Tohen M, Kryzhanovskaya L, Carlson G, DelBello M, Wozniak J, Kowatch R, Wagner K, Findling R, Lin D, Robertson-Plouch C, Xu W, Dittmann RW, Biederman J: Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 164:1547-1556, 2007.
57. Townsend L, Findling RL: Modifying the risk of atypical antipsychotics in the treatment of juvenile-onset schizophrenia. Expert Opin Pharmacother 11:195-205, 2010.
58. Tsai SY, Lee HC, Chen CC, Huang YL: Cognitive impairment in later life in patients with early-onset bipolar disorder. Bipolar Disord 9:868-875, 2007.
59. Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B, for the Trial 144 Study Investigators: Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (trial 144: A randomized controlled study). J Clin Psychiatry 72:1452-1464, 2011.
60. Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry 133:429-435, 1978.
61. Zeni CP, Tramontina S, Ketzer CR, Pheula GF, Rohde LA: Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder: A randomized crossover trial. J Child Adolesc Psychopharmacol 19:553-561, 2009.